Clinical Trial Update: A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating FDA022-BB05 in patients with advanced solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• FDA022-BB05

Snippet

Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Conditions: Advanced Solid Tumors | Phase 1 | Status: RECRUITING